A biopharmaceutical company in Germantown, Maryland, that develops precision medicines for cancer, autoimmune disorders, and infectious diseases. It grew out of Intrexon, a synthetic biology firm founded in 1998, and in 2020 the whole company rebranded as Precigen to focus entirely on human health. Its name blends "precision" and "genetics," and its UltraCAR-T platform can engineer a patient's own immune cells overnight at the hospital using a non-viral "Sleeping Beauty" gene-delivery system.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +6.55M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.